| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.24 | 2e-15 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | -0.21 | 7e-12 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | -0.22 | 2e-11 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.22 | 1e-10 |
| mRNA | SN-38 | CTRPv2 | pan-cancer | AAC | -0.25 | 2e-10 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.22 | 3e-10 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | -0.2 | 4e-10 |
| mRNA | Vorinostat | GDSC1000 | pan-cancer | AAC | -0.2 | 9e-10 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.19 | 1e-09 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | -0.2 | 2e-09 |